Loading...
•
Dec 31, 2022
Ironwood Pharmaceuticals Q4 2022 Earnings Report
Reported fourth quarter and full year results, achieving GAAP and non-GAAP net income of $175 million for the year and ending the year with $656 million in cash and cash equivalents.
Key Takeaways
Ironwood Pharmaceuticals reported its fourth quarter and full year 2022 results, with full year LINZESS U.S. net sales growth lower than expected due to inventory fluctuations, but delivered adjusted EBITDA guidance of over $250 million. The company ended the year with a strong balance sheet and is focused on investing in LINZESS and pursuing GI assets.
2022 GAAP and non-GAAP net income of $175 million
2022 adjusted EBITDA of $252 million
Ended 2022 with $656 million in cash and cash equivalents
FDA granted priority review to the sNDA for LINZESS for the treatment of functional constipation in pediatric patients aged 6 to 17 with a PDUFA date in the second quarter of 2023
Forward Guidance
Ironwood anticipates a number of exciting milestones this year, and believe Ironwood is well positioned to deliver long term growth and value to patients and shareholders. Ironwood has assumed that it will not incur material expenses related to business development activities in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...